Collectively, the observations presented here represent, to our knowledge, the first utilization of engineered MSC exosomes as a method to deliver both zinc finger activator proteins and mRNAs to increase CFTR expression and might suggest that such a method could be expanded upon as a genetic therapy to therapeutically bolster CFTR expression in those patients that do not respond to the current therapies or as an adjunctive cellular therapeutic approach to treating CF. The gene discussed is CFTR; the disease is cystic fibrosis.